Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-07-09 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 기술도입 계약 해지)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding the termination of a technology licensing agreement for an Antibody-Drug Conjugate (ADC) platform. It details the reasons for the termination (patent issues) and the financial implications (non-refundable upfront payment). Since this is a specific corporate announcement regarding a material business event (contract termination) that does not fit into categories like M&A, share issues, or financial reports, it is classified as a general regulatory filing.
2025-07-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of the company's major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-04 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (IND) 승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding a 'Correction Report' (정정신고) for a previously disclosed 'Major Management Matter' (투자판단 관련 주요경영사항) concerning an IND (Investigational New Drug) application for a clinical trial. It details updates to the clinical trial approval agencies (adding Australia's HREC) and the submission date. As this is a formal regulatory disclosure filed with the exchange (KRX) regarding clinical trial status, it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, Earnings, or Dividends.
2025-06-11 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (IND) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a clinical trial (IND) for a drug candidate (ABL103). It details the regulatory approval status from the FDA and MFDS, clinical trial objectives, and methodology. Since it is a formal regulatory disclosure of a material business event that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-06-04 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for ABL Bio, covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial data, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-13 Korean
[기재정정]투자판단관련주요경영사항 (IGF1R 기반 BBB 셔틀 플랫폼 GrabodyB(뇌혈관장벽 투과 기술) 기술이전 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically a correction (정정신고) to a previous technology transfer agreement disclosure. It details the receipt of an upfront payment related to a licensing deal with GSK. Since this is a formal regulatory disclosure of a material business event (a contract update/milestone), it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to corporate takeovers/mergers) or other specialized reports.
2025-05-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.